The 455 Adverse Event Reports: What the FDA Compounded GLP-1 Data Actually Says
The FDA's headline number — 455+ adverse events from compounded semaglutide — is driving policy. But what do those reports actually contain? Here's a sourced analysis.
455+ adverse event reports for compounded semaglutide (by early 2025)
320+ reports for compounded tirzepatide
Most common cause cited: Dosing errors from multi-dose vials
Some required hospitalization
What the FDA Reported
By early 2025, the FDA had received over 455 adverse event reports linked to compounded semaglutide and more than 320 for compounded tirzepatide. According to the FDA, many involved dosing errors from patients self-administering incorrect doses from multi-dose vials — some requiring hospitalization.1
Context: The Denominator Problem
During the shortage period (2022-2024), millions of patients used compounded GLP-1 medications. 455 adverse events against a denominator of millions represents a very low absolute rate. For comparison:
- Brand-name Ozempic has accumulated thousands of adverse event reports since 2017, which is expected for any widely-used medication
- FAERS (the FDA's reporting system) captures a fraction of actual events — estimated at 1-10% of real occurrences2
- The severity matters more than the count — hospitalization cases are the most concerning
The Dosing Error Pattern
The FDA specifically flagged dosing errors from multi-dose vials as a primary driver. This is a delivery format issue, not necessarily a drug quality issue. Brand-name pens use pre-set doses, eliminating this error source. Multi-dose vials require patients to draw up correct volumes using insulin syringes — a process with inherent error potential.
This distinction matters because it suggests the risk can be mitigated through better patient education and pre-filled delivery formats, not just by eliminating compounding entirely.
BB Health+ · $179/mo sema
Compare Provider Options →Compounded medications are not FDA-approved. Paid link
The Quality Question
Separate from adverse events, Novo Nordisk's litigation alleged impurity levels as high as 86% in some tested compounded products.3 Important caveats:
- These are allegations in litigation, not peer-reviewed findings
- The testing methodology and sample selection haven't been independently verified
- The figure likely represents outliers, not typical compounding quality
- Many 503B facilities operate under cGMP standards with rigorous quality controls
Source note: We report the FDA's data and Novo Nordisk's claims as stated. We do not have access to the underlying FAERS reports or the independent testing data to verify the specific numbers. Readers should weigh these claims accordingly.
Provider Options
$239/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
from $199/mo
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
The Source Summary
455 adverse events sounds alarming until you consider millions of users — the absolute rate is very low. Dosing errors from multi-dose vials are a legitimate concern that better delivery formats can address. Quality allegations from litigation should be weighed carefully. The data supports caution and improved standards, not necessarily the elimination of all compounding.
Sources
- Pharmacy Times. FDA adverse event data cited in 503B proposal, May 2026.
- FDA. FAERS reporting rates estimated at 1-10% of actual occurrences.
- Novo Nordisk litigation filings. Impurity testing allegations, 2025-2026.